XML 49 R32.htm IDEA: XBRL DOCUMENT v3.21.1
Acquisitions - Additional Information (Details)
1 Months Ended 3 Months Ended
Feb. 28, 2021
USD ($)
Milestone
Oct. 31, 2020
USD ($)
Milestone
May 31, 2020
USD ($)
Milestone
Sep. 30, 2016
USD ($)
$ / shares
Mar. 31, 2021
USD ($)
Milestone
Dec. 31, 2020
USD ($)
Jan. 31, 2018
USD ($)
Aug. 31, 2017
USD ($)
TomegaVax | TomegaVax Letter Agreement                
Business Acquisition [Line Items]                
Milestone payments aggregate amount payable, maximum       $ 30,000,000.0        
Minimum common stock conversion price for milestone payments consideration | $ / shares       $ 45        
Milestone payments related terms         the Company will be required to pay to the former stockholders of TomegaVax milestone payments of up to an aggregate of $30.0 million if the per-share price of the Company’s publicly traded common stock, or implied price per share of the Company’s Series A-1 convertible preferred stock (or common stock upon conversion) upon a certain asset sale, merger or stock sale, is at least $45 (as adjusted in the case of any stock dividend, stock split or other similar recapitalization), with the amount of such payments determined by the share price and the stage of the Company’s clinical development at the time of the relevant event triggering the payment.      
Number of milestones achieved | Milestone 1              
Contingent consideration recognized $ 10,000,000.0              
Milestone payments, amount payable term 90 days              
Estimated fair value of embedded derivative         $ 7,100,000      
Humabs                
Business Acquisition [Line Items]                
Contingent consideration recognized         63,300,000 $ 29,200,000    
Humabs | HBV Product                
Business Acquisition [Line Items]                
Contingent consideration recognized         $ 63,300,000      
Additional consideration payable upon achievement of specified milestone events, maximum               $ 135,000,000.0
Number of specified clinical milestones achieved | Milestone     1          
Specified clinical development milestones payment     $ 10,000,000.0          
Humabs | Another Product                
Business Acquisition [Line Items]                
Additional consideration payable upon achievement of specified milestone events, maximum               $ 105,000,000.0
Humabs | SARS-CoV-2 Product                
Business Acquisition [Line Items]                
Number of specified clinical milestones achieved | Milestone   1            
Specified clinical development milestones payment   $ 10,000,000.0            
Agenovir                
Business Acquisition [Line Items]                
Number of milestones achieved | Milestone         0      
Contingent consideration recognized         $ 0      
Agenovir | HBV Product                
Business Acquisition [Line Items]                
Milestone payments aggregate amount payable, maximum             $ 135,000,000.0